Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China; Lanzhou University Institute of Health Data Science, Lanzhou, China.
School of Public Health, Lanzhou University, Lanzhou, China.
J Clin Epidemiol. 2022 Apr;144:163-172. doi: 10.1016/j.jclinepi.2021.12.015. Epub 2021 Dec 14.
To describe the current status of COVID-19 vaccine guidelines.
We searched databases, Google and guideline platforms to retrieve COVID-19 vaccine guidelines published between January 1, 2020 and July 8, 2021. We worked in pairs to identify the eligible guidelines and extract data of whether the methodology, funding, and conflict of interests were assessed/reported, and so on. Results were presented descriptively.
A total of 106 COVID-19 vaccine guidelines were included. In the first half of 2021, on average 15 guidelines were published every month. Fifty (47.2%) guidelines addressed the vaccination of people with specific medical conditions, and 18 (17.0%) guidelines focused on adverse effects after vaccination. Only 28 (26.4%) guidelines reported the methodology they used. Four (3.8%) of guidelines assessed both the quality of evidence and strength of recommendations; 42 (39.6%) and 65 (61.3%) guidelines reported their funding sources and conflict of interest, respectively. Most guidelines were published in English (n = 92, 86.8%).
A high number of guidelines on COVID-19 vaccines have been published in the recent months, but most of them lack clear and transparent reporting of methodology, funding, and conflicts of interest. Rigorous methodological and reporting quality evaluation of these guidelines is needed.
描述 COVID-19 疫苗指南的现状。
我们搜索了数据库、Google 和指南平台,以检索 2020 年 1 月 1 日至 2021 年 7 月 8 日期间发布的 COVID-19 疫苗指南。我们两人一组识别合格的指南,并提取有关方法学、资金和利益冲突是否评估/报告等数据。结果以描述性方式呈现。
共纳入 106 项 COVID-19 疫苗指南。2021 年上半年,平均每月发布 15 项指南。50 项(47.2%)指南针对具有特定医疗条件的人群的疫苗接种,18 项(17.0%)指南关注疫苗接种后的不良反应。只有 28 项(26.4%)指南报告了他们使用的方法学。有 4 项(3.8%)指南评估了证据质量和推荐强度;42 项(39.6%)和 65 项(61.3%)指南分别报告了资金来源和利益冲突。大多数指南以英文发表(n=92,86.8%)。
最近几个月发布了大量关于 COVID-19 疫苗的指南,但大多数指南缺乏对方法学、资金和利益冲突的明确和透明报告。需要对这些指南进行严格的方法学和报告质量评估。